Table 1.
Baseline characteristics, treatment and health outcomes of patients admitted with acute ischemic stroke.
| Total cohort (n=110) | mRS (≤2) (n=45) | mRS (>2) (n=65) | P | |
|---|---|---|---|---|
| Age (years) | 67.0 (14.7) | 60.1 (13.9) | 71.8 (13.4) | <.001 |
| Male | 59 (53.6) | 23 (51.1) | 36 (55.4) | .700 |
| Hypertension | 83 (75.5) | 31 (68.9) | 52 (80.0) | .183 |
| Smoking | 18 (16.4) | 11 (16.9) | 7 (15.6) | .183 |
| Diabetes mellitus | 60 (54.6) | 25 (55.6) | 35 (53.9) | .859 |
| Dyslipidemia | 32 (29.1) | 13 (28.9) | 19 (29.2) | .969 |
| Atrial fibrillation | 14 (12.7) | 0 | 14 (21.5) | <.001 |
| Ischemic heart disease | 24 (21.8) | 7 (15.7) | 17 (26.2) | .217 |
| Chronic kidney disease | 19 (17.3) | 6 (13.3) | 13 (20.0) | .450 |
| Peripheral Arterial disease | 4 (3.6) | 1 (2.2) | 3 (4.6) | .510 |
| Prior stroke | 27 (24.5) | 4 (8.9) | 23 (35.4) | <.001 |
| Thrombolytic therapy | 8 (7.3) | 3 (6.7) | 5 (7.7) | .839 |
| Aspirin or clopidogrel | 25 (22.7) | 12 (26.7) | 13 (20.0) | .701 |
| Aspirin and clopidogrel | 82 (74.6) | 32 (71.1) | 50 (77.0) | .701 |
| Anticoagulant alone | 19 (17.3) | 5 (11.1) | 14 (21.5) | .380 |
| Antiplatelet + anticoagulant | 4 (3.6) | 2 (3.1) | 2 (3.1) | |
| Median length of hospitalization (days) | 7 (5–11) | 7 (5–9) | 7 (5–12) | .8644 |
| Median follow up (months) | 29.3 (23.9) | 34.0 (10.5) | 25.4 (25.8) | <.001 |
| mRS on discharge | 3.3 (2.1) | 1.1 (0.8) | 4.9 (0.9) | <.001 |
| mRS on follow up | 3.4 (2.9) | 1 (0–3) | 4.6 (4.9) | <.001 |
| Mortality | 40 (36.4) | 4 (8.9) | 36 (55.38) | <.001 |
Data are n (%) or mean (standard deviation) for age, or median (interquartile range) for length of hospitalization and follow-up time. mRS: modified Rankin Scale; IQR: interquartile range.